Sagespring Wealth Partners LLC Has $1.38 Million Position in Boston Scientific Corporation $BSX

Sagespring Wealth Partners LLC raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 10.6% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 12,836 shares of the medical equipment provider’s stock after acquiring an additional 1,230 shares during the quarter. Sagespring Wealth Partners LLC’s holdings in Boston Scientific were worth $1,379,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock worth $1,677,124,000 after buying an additional 834,274 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after buying an additional 1,383,524 shares during the period. Amundi boosted its holdings in shares of Boston Scientific by 2.6% during the 1st quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock worth $1,212,408,000 after buying an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Boston Scientific by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock valued at $1,139,938,000 after purchasing an additional 460,580 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on BSX shares. UBS Group boosted their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Finally, Raymond James Financial upped their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific currently has an average rating of “Buy” and a consensus target price of $120.71.

Boston Scientific Stock Up 1.4%

Shares of NYSE BSX opened at $96.26 on Wednesday. The stock has a market capitalization of $142.63 billion, a P/E ratio of 57.30, a P/E/G ratio of 2.29 and a beta of 0.61. The company has a 50-day moving average price of $101.58 and a 200-day moving average price of $101.80. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s revenue was up 22.8% on a year-over-year basis. During the same period last year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last ninety days. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.